Skip to main content
Clinical Trials/EUCTR2015-002923-24-BE
EUCTR2015-002923-24-BEActive, not recruitingPhase 1

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Prospective Study to Evaluate the Safety and Efficacy of Domperidone in 6-month-old to 12-year-old Pediatric Subjects With Nausea and Vomiting Due to Acute Gastroenteritis

Janssen-Cilag International NV0 sites480 target enrollmentStarted: March 15, 2016Last updated:
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
480

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • - The participant presents with at least 3 episodes of nonbilious, non-bloody vomiting within the 24 hours prior to visiting the physician’s office.
  • - The participant has at least 2 signs and symptoms other than vomiting consistent with acute gastroenteritis (AG) (example, fever, nausea, diarrhea, abdominal pain, bloating, or discomfort) within 3 hours prior to visiting the physician’s office
  • - The participant has mild-to-moderate dehydration
  • - The participant had at least 1 episode of non-bloody diarrhea within the 24 hours prior to the visiting the physician’s office
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 480
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • - The participant has severe dehydration or severe malnutrition
  • - The participant who has vomiting and clinical symptoms for longer than 72 hours prior to the baseline physician’s office visit
  • - The participant needs intravenous (IV) fluid replacement
  • - The participant has chronic severe diarrhea, a previous history of Helicobacter pylori infection or received treatment for H. pylori-induced gastritis, active peptic ulcer, celiac disease, Crohn’s disease, ulcerative colitis, eosinophilic esophagitis, malabsorption, short bowel syndrome, post-viral gastroparesis, cyclic vomiting syndrome, or previous gastrointestinal surgery
  • - The participant has upper respiratory symptoms such as cough, congestion, otitis media or pharyngitis

Investigators

Similar Trials

Active, not recruiting
Phase 1
A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Nemolizumab in Subjects with Chronic Kidney Disease with Associated Severe PruritusChronic Kidney Disease Associated Severe PruritusMedDRA version: 24.1Level: PTClassification code 10037087Term: PruritusSystem Organ Class: 10040785 - Skin and subcutaneous tissue disorders
EUCTR2021-004766-35-HUGalderma S.A.252
Active, not recruiting
Not Applicable
A Multicenter, Double-blind, Randomized, Placebo-controlled, Repeat Treatment (two cycle) Study of the Safety and Efficacy of AGN-214868 in Patients with Postherpetic NeuralgiaPhase II study to investigate the safety and efficacy of AGN-214868 compared to placebo in the treatment of postherpetic neuralgia The study will look at patients with postherpetic neuralgia (PHN) of at least 9 months duration after the onset of a herpes zoster skin rash who have an area of pain affecting either the cervical, thoracic, lumbar, or sacral dermatomes.MedDRA version: 14.0Level: LLTClassification code 10054095Term: Neuropathic painSystem Organ Class: 10029205 - Nervous system disorders
EUCTR2010-020977-18-DEAllergan Ltd280
Active, not recruiting
Not Applicable
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel group, Event driven, Phase III study to assess the effects of ACT-064992 on Morbidity and Mortality in patients with Symptomatic Pulmonary Arterial Hypertension - SERAPHIMedDRA version: 9.1Level: LLTClassification code 10037405Term: Pulmonary hypertension primaryPulmonary Arterial Hypertension
EUCTR2007-002440-14-ITActelion Pharmaceuticals Ltd.525
Active, not recruiting
Phase 1
A study to evaluate the effect of a single dose of zolmitriptan (Zomig)nasal spray (0.5 mg, 2.5 mg, or 5 mg) as compared to placebo (0 mg) for the treatment of migraine headaches in children/adolescents ages 12 to 17Acute Migraine Headache in AdolescentsMedDRA version: 14.1Level: LLTClassification code 10066635Term: Acute migraineSystem Organ Class: 100000004852
EUCTR2010-019203-31-FIAstraZeneca AB798
Active, not recruiting
Phase 1
A Study to Evaluate the Safety and Efficacy of Domperidone in Pediatric Participants With Nausea and Vomiting Due to Acute Gastroenteritisausea and Vomiting Due to Acute GastroenteritisMedDRA version: 18.1 Level: LLT Classification code 10066762 Term: Acute gastroenteritis System Organ Class: 100000004862
EUCTR2015-002923-24-GBJanssen-Cilag International NV292